BRAINSTORM CELL THERAPEUTICS INC. Pre-Tax Income
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported Pre-Tax Income of -$10.31 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-03-31
- BRAINSTORM CELL THERAPEUTICS INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$10.31M.
- BRAINSTORM CELL THERAPEUTICS INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$11.62M.
- BRAINSTORM CELL THERAPEUTICS INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$17.19M.
- BRAINSTORM CELL THERAPEUTICS INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$24.28M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|
| 2025-12-31 | -$10.31M 10-K · filed 2026-03-31 |
| 2024-12-31 | -$11.62M 10-K · filed 2026-03-31 |
| 2023-12-31 | -$17.19M 10-K · filed 2025-03-31 |
| 2022-12-31 | -$24.28M 10-K · filed 2024-04-01 |
| 2021-12-31 | -$24.46M 10-K · filed 2023-03-30 |
| 2020-12-31 | -$31.81M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |